Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.42 - $4.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)930.30K
Market Cap
$318.14M
Enterprise Value$80.81M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 26, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding83,942,406
10 Day Avg. Volume1,257,397
30 Day Avg. Volume930,298
Standard Deviation0.20
R-Squared0.09
Alpha-0.00120
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1518.11
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.84
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$21.80Price Target Upside392.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe independent DSMB recommended the Phase 3 EFZO-FIT trial in pulmonary sarcoidosis to continue without any modifications.
Competitor AnalysisCompetitor Kinevant's Phase 2 RESOLVE-Lung study with namilumab failed to show treatment benefit, highlighting the promising nature of efzofitimod in comparison.
Bears Say
Data TimelineExpected updates from aTyr's programs include a significant focus on long-term data, which might delay immediate results.
---
Ownership Overview
2.67% Insiders
30.32% Mutual Funds
13.12% Other Institutional Investors
49.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $1.42 and its highest was $4.29 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $318.14M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Nov 07, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.01.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.23.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 83,942,406 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went up 0.645%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
---
aTyr Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.80 (392.10% Upside)
$21.80 (392.10% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.63%
12-Months-Change
Fundamentals
Return on Equity
-77.96%
Trailing 12-Months
Asset Growth
-26.75%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
---
ATYR Stock 12 Month Forecast
Average Price Target
$21.80
▲(392.10% Upside)
Technical Analysis
Fate Therapeutics
―
Blueprint Medicines
―
Seres Therapeutics
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Best Analysts Covering ATYR
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+86.95%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +86.95% per trade.
---